


# Cortellis Competitive Intelligence

## 特定の薬事指定を受けた医薬品を検索する

Competitive Intelligenceは薬事指定を受けた医薬品について、指定の種類から検索対象を絞り込むことが可能です。薬事指定の種類は以下の通りです。

- Orphan Drug
- Fast Track
- Priority Review
- Breakthrough Therapy
- Paediatric Investigation Plan
- Accelerated Approval
- Rare Pediatric Disease
- Qualified Infectious Disease Product
- Clinically Urgent Foreign Drug
- Tropical Disease Priority Review
- PRIME
- National Science and Technology Major Project
- Regenerative Medicine Advanced Therapy
- Advanced Therapy Medicinal Product
- Promising Innovative Medicine
- Sakigake
- Special Review Project
- Animal Rule
- Emergency Use Authorization
- New Active Substance



SHOW ALL FILTERS


Search Regulatory Designation Look up Select filter view Frequency

Therapy Area  
Indication  
Company  
Status  
Country/Territory  
Target-based Actions  
Other Actions  
Technologies  
Added Date  
Last Change Date  
Highest Status  
Highest Status at Termination  
Reason for Discontinuation  
**Regulatory Designations**  
Total Reported Sales 2020 (USD M)

Orphan Drug (4127)  
Fast Track (1422)  
Priority Review (505)  
Breakthrough Therapy (396)  
Paediatric Investigation Plan (351)  
Rare Pediatric Disease (266)  
Accelerated Approval (201)  
Qualified Infectious Disease Product (136)  
PRIME (97)  
Clinically Urgent Foreign Drug (76)  
Emergency Use Authorization (61)  
Regenerative Medicine Advanced Therapy (56)  
National Science and Technology Major Project (52)  
Promising Innovative Medicine (46)

Cancel Apply

FilterのRegulatory Designationsから薬事指定の種類を選択可能です。



sintilimab

Snapshot Highlight Search Terms & Synonyms < Previous Next >

Latest Press Releases  
Latest Event Transcripts  
Broker Research Reports  
Development Profile  
Literature Review  
Development Status  
**Regulatory Designations**  
Milestones  
Chemical Structures  
Drug Names  
Sales and Forecasts

ORPHAN DRUG

| Indication                 | Awarded Indication                      | Company                 | Country/Territory | Status           | Type      | Date        | Source                  |
|----------------------------|-----------------------------------------|-------------------------|-------------------|------------------|-----------|-------------|-------------------------|
| Esophagus tumor            | Treatment of esophageal cancer          | Innovent Biologics Inc. | US                | Granted          | Treatment | 14-Apr-2020 | <a href="#">Z268261</a> |
| Peripheral T-cell lymphoma | Treatment of peripheral T-cell lymphoma | Innovent Biologics Inc. | EU                | Granted          | Treatment | 28-Feb-2020 | <a href="#">Z260948</a> |
| Peripheral T-cell lymphoma | Treatment of peripheral T-cell lymphoma | Innovent Biologics Inc. | EU                | Positive Opinion | Treatment | 22-Jan-2020 | <a href="#">Z240834</a> |

PRIORITY REVIEW

| Indication       | Awarded Indication | Company                 | Country/Territory | Status  | Type | Date        | Source                  |
|------------------|--------------------|-------------------------|-------------------|---------|------|-------------|-------------------------|
| Hodgkins disease | Hodgkins disease   | Innovent Biologics Inc. | China             | Granted |      | 23-Apr-2018 | <a href="#">2026612</a> |

医薬品レポートにて、画面左のタブからRegulatory Designationsを選択すると、薬事指定の種類ごとに指定を受けた開発プログラム一覧をご確認頂けます。